Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.56 |
| ▸ | PDE6C | P51160 | 8/20 | 0.45 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634306 | 1.00 | PDE5A (0.56) | PDE5APDE6CPDE11A | |
| SCHEMBL6407726 | 0.86 | PDE5A (0.59) | PDE5APDE6CPDE11A | |
| SCHEMBL1891582 | 0.86 | PDE5A (0.59) | PDE5APDE6CPDE11A | |
| SCHEMBL6412001 | 0.75 | KDM4E (0.36) | PDE5A | |
| SCHEMBL5530466 | 0.71 | PDE5A (0.84) | PDE5A | |
| SCHEMBL1887265 | 0.71 | PDE5A (0.84) | PDE5A | |
| SCHEMBL6407365 | 0.64 | PDE5A (0.80) | PDE5A | |
| SCHEMBL6407149 | 0.62 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6412812 | 0.62 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6345084 | 0.54 | GAA (0.45) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | SUI ZHIHUA (US) | 2004-03-04 | — | — | US | claimed |
| US-6635638-B2 | Treatment of sexual dysfunction, cardiovascular system disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | claimed |
| US-20150086504-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-20110112115-A1 | POLYMERIC MICROEMULSIONS | ARIEN ALBERTINA MARIA EDUARDA | 2011-05-12 | — | — | US | disclosed |
| EP-1504047-B1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | EP | disclosed |
| US-20060034797-A1 | Polymeric micromulsions | ETHICON INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1504047-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003093344-A1 | POLYMERIC MICROEMULSIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044021-A1 | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE6C 30/4885PDE11A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.